TRT and LH Suppression: What It Means for Your Body
Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM
Testosterone Replacement Therapy (TRT) consistently leads to the suppression of Luteinizing Hormone (LH) production by the pituitary gland. This suppression is a direct consequence of the body's negative feedback system, effectively halting natural testosterone synthesis in the testes.
TRT and LH Suppression: What It Means for Your Body
When you embark on Testosterone Replacement Therapy (TRT), one of the most significant physiological changes you'll experience is the suppression of Luteinizing Hormone (LH). LH, produced by your pituitary gland, acts as a critical messenger, signaling your Leydig cells in the testes to produce testosterone. Introducing exogenous testosterone into your system triggers a natural feedback mechanism that tells your pituitary to reduce or cease its LH output.
This isn't an accidental side effect; it's a direct and expected consequence of TRT. Your body strives for hormonal balance. When it detects sufficient testosterone from an external source, it downregulates its internal production pathways. This negative feedback loop primarily impacts the hypothalamus (reducing GnRH) and the pituitary gland (reducing LH and FSH).
The Mechanism of LH Suppression
The mechanism is straightforward: high levels of circulating testosterone, whether endogenous or exogenous, inhibit the release of GnRH from the hypothalamus and directly suppress LH secretion from the pituitary. Studies have consistently shown that men on TRT will experience a significant drop in LH levels, often to undetectable ranges [1]. This suppression can occur rapidly, within weeks of initiating therapy, and is generally more pronounced with longer-acting testosterone preparations compared to shorter-acting ones [2].
The consequence of suppressed LH is a reduction in the stimulation of Leydig cells. These cells are responsible for producing approximately 95% of your body's natural testosterone. Without adequate LH signaling, they become quiescent, leading to a cessation of endogenous testosterone production and, often, a decrease in testicular size (atrophy). This is why monitoring LH levels is a standard part of TRT management, helping practitioners understand the degree of HPG axis suppression.
Nuances and Clinical Considerations
While LH suppression is a given with TRT, its implications vary based on individual circumstances. For men who are not concerned with fertility, LH suppression is often an acceptable trade-off for the benefits of optimized testosterone levels. However, for those who wish to preserve fertility, LH suppression presents a challenge. Without LH, natural testosterone production in the testes ceases, which is detrimental to spermatogenesis.
In such cases, strategies like co-administering Human Chorionic Gonadotropin (HCG) are often employed. HCG mimics the action of LH, directly stimulating the Leydig cells to produce intratesticular testosterone, thereby helping to maintain testicular function and, in many cases, preserve spermatogenesis despite the pituitary's suppressed LH output [3]. It's a way to bypass the suppressed pituitary signal and keep the testes active.
Comparison: LH Levels On and Off TRT
| Condition | LH Levels | Endogenous Testosterone Production | Testicular Size |
|---|---|---|---|
| Healthy Male (No TRT) | Normal, pulsatile | Active | Normal |
| On TRT (No HCG) | Suppressed (often undetectable) | Ceased or significantly reduced | Often reduced (atrophy) |
| On TRT (With HCG) | Suppressed (pituitary still affected) | Stimulated by HCG (mimics LH) | Maintained or less reduction |
Practical Takeaway
If you're on TRT, expect your LH levels to be suppressed, which means your body's natural testosterone production will halt. If maintaining fertility or testicular size is important to you, discuss with your doctor the option of incorporating HCG into your TRT protocol to mitigate these effects.
References
- Miranda, E. P., et al. (2022). Luteinizing Hormone Suppression Profiles in Men Treated with Testosterone Therapy. The Journal of Sexual Medicine, 19(9), 1359-1365.
- Masterson, T. A., et al. (2021). The Effect of Longer-Acting vs Shorter-Acting Testosterone Preparations on Follicle-Stimulating Hormone and Luteinizing Hormone Suppression. The Journal of Sexual Medicine, 18(1), 163-170.
- Lee, J. A. (2018). Indications for the use of human chorionic gonadotropic. Translational Andrology and Urology, 7(4), 601â608.